AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18411833 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma psychoeducation program with family therapy
Number of subjects: 46
Study 18411833 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 46
Study 18411833 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (intervention)
Number of subjects: 46
Study 17067250 — intervention group
Group type: EXPERIMENTAL
Intervention: HoMBReS: Hombres Manteniendo Bienestar y Relaciones Saludables intervention
Number of subjects: 0
Study 15599116 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 28
Study 15599116 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 28
Study 10714568 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy consisting of stavudine + lamivudine + nelfinavir + saquinavir for 26 weeks
Number of subjects: 65
Study 9172053 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance for 20 minutes
Number of subjects: 10
Study 9172053 — intervention group
Group type: COMPARATOR
Intervention: Rest for 20 minutes
Number of subjects: 10
Study 8482307 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 200
Study 8482307 — intervention group
Group type: COMPARATOR
Intervention: metronidazole/gentamicin
Number of subjects: 200
Study 3982268 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE‐EX (N = 16) - Progressive walking program (4 days/week for 9 weeks) at 80% HRM
Number of subjects: 38
Study 3982268 — intervention group
Group type: EXPERIMENTAL
Intervention: POST‐EX (N = 14) - Progressive walking program (4 days/week for 9 weeks) at 80% HRM
Number of subjects: 38
Study 3982268 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 38
Study 2836204 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol 100 mg
Number of subjects: 8
Study 2836204 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol 200 mg
Number of subjects: 8
Study 2836204 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 8
Study 29117643 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated activated charcoal haemoperfusion (CAC‐HP) plus standard care (oral activated charcoal)
Number of subjects: 14
Study 29117643 — intervention group
Group type: COMPARATOR
Intervention: Standard care (oral activated charcoal)
Number of subjects: 14
Study 26335917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 62
Study 26335917 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 62
Study 24318788 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (20‐min warm‐up program performed twice weekly for 10 weeks)
Number of subjects: 30
Study 24318788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 24318788 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Number of subjects: 30
Study 24318788 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 23322920 — intervention group
Group type: EXPERIMENTAL
Intervention: High job demands
Number of subjects: 12550
Study 23322920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low job control
Number of subjects: 12550
Study 23322920 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged standing
Number of subjects: 12550
Study 23322920 — intervention group
Group type: EXPERIMENTAL
Intervention: Awkward lifting
Number of subjects: 12550
Study 23322920 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting/kneeling
Number of subjects: 12550
Study 21432597 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 21432597 — intervention group
Group type: EXPERIMENTAL
Intervention: If-then plans
Number of subjects: 0
Study 18438059 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolisation
Number of subjects: 2
Study 18438059 — intervention group
Group type: COMPARATOR
Intervention: Surgery (hysterectomy or myomectomy)
Number of subjects: 2
Study 18438059 — intervention group
Group type: COMPARATOR
Intervention: Uterine artery embolisation and Surgery
Number of subjects: 2
Study 16893278 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Workplace (n=22)
Number of subjects: 47
Study 16893278 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (n=25)
Number of subjects: 47
Study 15328673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride (20, 60, 120, or 240 mg twice daily)
Number of subjects: 857
Study 15328673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 857
Study 11247146 — intervention group
Group type: EXPERIMENTAL
Intervention: Turpentine white emulsion baths
Number of subjects: 100
Study 11247146 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride baths
Number of subjects: 100
Study 9591449 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids treatment
Number of subjects: 22
Study 9591449 — intervention group
Group type: COMPARATOR
Intervention: Post myocardial infarction syndrome (PMIS)
Number of subjects: 22
Study 9591449 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 9591449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial effusion
Number of subjects: 22
Study 8401048 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream applied twice daily for one week
Number of subjects: 256
Study 8401048 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 1% cream applied twice daily for four weeks
Number of subjects: 256
Study 3780287 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic salbutamol (200 micrograms 4-times daily)
Number of subjects: 17
Study 3780287 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic placebo inhaler (2 actuations 4-times daily)
Number of subjects: 17
Study 31869402 — intervention group
Group type: EXPERIMENTAL
Intervention: Second language (L2) training for 8 weeks
Number of subjects: 11
Study 31869402 — intervention group
Group type: COMPARATOR
Intervention: Control group (HCs)
Number of subjects: 11
Study 29901486 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program with mindfulness training (n = 100)
Number of subjects: 194
Study 29901486 — intervention group
Group type: COMPARATOR
Intervention: Weight loss program without mindfulness training (n = 94)
Number of subjects: 194
Study 29901486 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program with or without mindfulness training
Number of subjects: 194
Study 26637959 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-obesity messages
Number of subjects: 0
Study 26637959 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obesity-related health messages
Number of subjects: 0
Study 26637959 — intervention group
Group type: COMPARATOR
Intervention: Neutral control task (word search)
Number of subjects: 0
Study 26637959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun exposure condition
Number of subjects: 0
Study 24481711 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral support of physical activity coupled with nutrition education
Number of subjects: 144
Study 24481711 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral methods for nutrition change
Number of subjects: 144
Study 23059810 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TNF-α mAb+methotrexate for 24 weeks
Number of subjects: 33
Study 23059810 — intervention group
Group type: COMPARATOR
Intervention: placebo+methotrexate for the first 12 weeks and anti-TNF-α mAb+methotrexate for another 12 weeks
Number of subjects: 33
Study 23059810 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TNF-α mAb+methotrexate
Number of subjects: 33
Study 19875685 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg oral for 7 days)
Number of subjects: 265
Study 19875685 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 7 days)
Number of subjects: 265
Study 18272040 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK (wg LASIK)
Number of subjects: 211
Study 18272040 — intervention group
Group type: COMPARATOR
Intervention: Conventional LASIK
Number of subjects: 211
Study 16032411 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 32
Study 16032411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12590148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivariate DNA/cytokeratin analysis
Number of subjects: 157
Study 12590148 — intervention group
Group type: COMPARATOR
Intervention: Univariate DNA analysis
Number of subjects: 157
Study 12590148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin-gated histograms
Number of subjects: 157
Study 11089515 — intervention group
Group type: COMPARATOR
Intervention: 40 mg rizatriptan
Number of subjects: 0
Study 11089515 — intervention group
Group type: COMPARATOR
Intervention: 5 mg rizatriptan
Number of subjects: 0
Study 11089515 — intervention group
Group type: COMPARATOR
Intervention: 10 mg rizatriptan
Number of subjects: 0
Study 9358715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanderbilt University Medical Center program (more intensive)
Number of subjects: 512
Study 9358715 — intervention group
Group type: COMPARATOR
Intervention: American Cancer Society program (less intensive)
Number of subjects: 512
Study 9358715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programs with nicotine-replacement therapy
Number of subjects: 512
Study 8252888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 6.25 mg/hr continuous infusion
Number of subjects: 167
Study 8252888 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 167
Study 2939542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleolysis with chymopapain (4,000 U of discase)
Number of subjects: 39
Study 2939542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (discography followed by injection of distilled water)
Number of subjects: 39
Study 31604088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular triamcinolone
Number of subjects: 0
Study 31604088 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 0
Study 31604088 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSESS tool
Number of subjects: 0
Study 31604088 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication analyses
Number of subjects: 0
Study 31102988 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D nasopharyngeal carcinoma (NPC)
Number of subjects: 5194
Study 31102988 — intervention group
Group type: COMPARATOR
Intervention: Type A nasopharyngeal carcinoma (NPC)
Number of subjects: 5194
Study 27492149 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutrition with more frequent feedback
Number of subjects: 1607
Study 27492149 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutrition with less frequent feedback
Number of subjects: 1607
Study 27492149 — intervention group
Group type: COMPARATOR
Intervention: Generalised dietary guidelines (Control)
Number of subjects: 1607
Study 27492149 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants interested in losing weight
Number of subjects: 1607
Study 27492149 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who skip meals
Number of subjects: 1607
Study 27492149 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who eat healthily frequently
Number of subjects: 1607
Study 27492149 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1607
Study 27492149 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants less than 45 years old
Number of subjects: 1607
Study 27492149 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 1607
Study 25974640 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine
Number of subjects: 535
Study 25974640 — intervention group
Group type: COMPARATOR
Intervention: Lantus® insulin glargine
Number of subjects: 535
Study 24130072 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-R (cyclophosphamide-Adriamycin-vincristine-prednisone-rituximab)
Number of subjects: 532
Study 24130072 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-RIT (CHOP followed by iodine-131 tositumomab radioimmunotherapy)
Number of subjects: 532
Study 24130072 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-R
Number of subjects: 532
Study 24130072 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-RIT
Number of subjects: 532
Study 24130072 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 532
Study 24130072 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH + β2M model
Number of subjects: 532
Study 24130072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients
Number of subjects: 532
Study 24130072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 532
Study 22108485 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula based on oligomeric proanthocyanidins (OPA)
Number of subjects: 36
Study 22108485 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula based on bioflavonoids
Number of subjects: 36
Study 22108485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19589522 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal stimulation using recombinant human FSH (rhFSH) and GnRH antagonist
Number of subjects: 0
Study 19589522 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist multiple-dose protocol (MDP)
Number of subjects: 0
Study 16310924 — intervention group
Group type: EXPERIMENTAL
Intervention: BXL628 150 mcg daily
Number of subjects: 119
Study 16310924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 15595296 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour low-intensity cycling for 4 days
Number of subjects: 11
Study 15595296 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour low-intensity cycling for 4 days
Number of subjects: 11
Study 15595296 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity cycling (1 and 3 hours)
Number of subjects: 11
Study 11084188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length measured by transvaginal ultrasound
Number of subjects: 760
Study 9061804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4)
Number of subjects: 14
Study 9061804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8238828 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium
Number of subjects: 69
Study 8238828 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium
Number of subjects: 69
Study 8238828 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium and suxamethonium
Number of subjects: 69
Study 2844338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cytomegalovirus immune globulin
Number of subjects: 97
Study 2844338 — intervention group
Group type: COMPARATOR
Intervention: Control (no intravenous cytomegalovirus immune globulin)
Number of subjects: 97
Study 29742109 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 50
Study 29742109 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (tolterodine 1 mg)
Number of subjects: 50
Study 27246708 — intervention group
Group type: EXPERIMENTAL
Intervention: PSS + NPWT
Number of subjects: 59
Study 27246708 — intervention group
Group type: COMPARATOR
Intervention: PSS alone
Number of subjects: 59
Study 25413975 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (combination of super-pulsed laser and light-emitting diodes)
Number of subjects: 13
Study 25413975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 13
Study 23428336 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Acetylcarnitine (LAC) plus placebo
Number of subjects: 80
Study 23428336 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/die plus placebo
Number of subjects: 80
Study 22012905 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 88
Study 22012905 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent application
Number of subjects: 88
Study 18438230 — intervention group
Group type: EXPERIMENTAL
Intervention: W+B (water + 5 g x L(‐1) betaine)
Number of subjects: 10
Study 18438230 — intervention group
Group type: EXPERIMENTAL
Intervention: C+B (6% carbohydrate-electrolyte fluid + 5 g x L(‐1) betaine)
Number of subjects: 10
Study 18438230 — intervention group
Group type: COMPARATOR
Intervention: C (6% carbohydrate-electrolyte fluid)
Number of subjects: 10
Study 18438230 — intervention group
Group type: COMPARATOR
Intervention: W (flavored, non-caloric water)
Number of subjects: 10
Study 16937274 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly 17.5 mg risedronate
Number of subjects: 496
Study 16937274 — intervention group
Group type: COMPARATOR
Intervention: Once-daily 2.5 mg risedronate
Number of subjects: 496
Study 12876107 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for Assessing Postnatal Problems (GAPP) educational programme
Number of subjects: 68
Study 12876107 — intervention group
Group type: EXPERIMENTAL
Intervention: GAPP educational programme
Number of subjects: 68
Study 11128859 — intervention group
Group type: EXPERIMENTAL
Intervention: 38 mg x kg(‐1) x d(‐1) of HMB
Number of subjects: 37
Study 11128859 — intervention group
Group type: EXPERIMENTAL
Intervention: 76 mg x kg(‐1) x d(‐1) of HMB
Number of subjects: 37
Study 11128859 — intervention group
Group type: COMPARATOR
Intervention: 0 mg x kg(‐1) x d(‐1) (Control)
Number of subjects: 37
Study 9083616 — intervention group
Group type: EXPERIMENTAL
Intervention: HECCM from viable pregnancies (n=11)
Number of subjects: 36
Study 9083616 — intervention group
Group type: EXPERIMENTAL
Intervention: HECCM from non-viable pregnancies (n=25)
Number of subjects: 36
Study 9083616 — intervention group
Group type: COMPARATOR
Intervention: Control media (n=17)
Number of subjects: 36
Study 9083616 — intervention group
Group type: EXPERIMENTAL
Intervention: All samples analyzed for IL-6
Number of subjects: 36
Study 8077790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution without venesection
Number of subjects: 0
Study 8077790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution with venesection
Number of subjects: 0
Study 8077790 — intervention group
Group type: COMPARATOR
Intervention: Control group (well hydrated with cristalloid saline solution)
Number of subjects: 0
Study 2808984 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-modulating minute ventilation VVIR pacing mode
Number of subjects: 10
Study 2808984 — intervention group
Group type: COMPARATOR
Intervention: Fixed-rate VVI pacing mode
Number of subjects: 10
Study 795379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide gel
Number of subjects: 335
Study 795379 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone benzoate gel
Number of subjects: 335
Study 31238919 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline + Capacity Building Intervention (GL + CBI)
Number of subjects: 49
Study 31238919 — intervention group
Group type: COMPARATOR
Intervention: Guideline only (GL-ONLY)
Number of subjects: 49
Study 31238919 — intervention group
Group type: COMPARATOR
Intervention: No guidelines (NO-GL)
Number of subjects: 49
Study 29149146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg with bupivacaine 0.25%
Number of subjects: 60
Study 29149146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 ug/kg with bupivacaine 0.25%
Number of subjects: 60
Study 29149146 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% alone (Control group)
Number of subjects: 60
Study 26711672 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal kissing
Number of subjects: 943
Study 26711672 — intervention group
Group type: COMPARATOR
Intervention: Sham kissing
Number of subjects: 943
Study 26711672 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 943
Study 25142189 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (60 μg/kg IV for 3 days before and after chemotherapy)
Number of subjects: 155
Study 25142189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 25142189 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 155
Study 23031471 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoors feeding system with 21-day regrowth of Digitaria decumbens grass
Number of subjects: 20
Study 23031471 — intervention group
Group type: COMPARATOR
Intervention: At pasture feeding system with 21-day regrowth of Digitaria decumbens grass
Number of subjects: 20
Study 23031471 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoors feeding system with 35-day regrowth of Digitaria decumbens grass
Number of subjects: 20
Study 23031471 — intervention group
Group type: COMPARATOR
Intervention: At pasture feeding system with 35-day regrowth of Digitaria decumbens grass
Number of subjects: 20
Study 23031471 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoors feeding system
Number of subjects: 20
Study 23031471 — intervention group
Group type: COMPARATOR
Intervention: At pasture feeding system
Number of subjects: 20
Study 19614803 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg)
Number of subjects: 154
Study 19614803 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg) + Aspirin (300 mg/d)
Number of subjects: 154
Study 19614803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 17599726 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 120
Study 16283848 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dry suture
Number of subjects: 14
Study 16283848 — intervention group
Group type: COMPARATOR
Intervention: Standard dry suture
Number of subjects: 14
Study 16283848 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified wet suture
Number of subjects: 14
Study 16283848 — intervention group
Group type: COMPARATOR
Intervention: Standard wet suture
Number of subjects: 14
Study 12100662 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-orientated care (EOC) training
Number of subjects: 16
Study 12100662 — intervention group
Group type: COMPARATOR
Intervention: Control homes (no specific intervention)
Number of subjects: 16